capricor
therapeutics
present
results
trial
duchenne
muscular
dystrophy
international
world
muscle
society
virtual
congress
final
results
phase
ii
trial
presented
october
los
angeles
globe
newswire
capricor
therapeutics
nasdaq
capr
biotechnology
company
focused
development
cell
therapeutics
treatment
prevention
diseases
announced
today
company
present
novel
data
randomized
phase
ii
clinical
trial
lead
investigational
product
boys
young
men
duchenne
muscular
dystrophy
dmd
craig
mcdonald
study
chair
cinrg
duchenne
natural
history
study
well
national
principal
investigator
capricor
study
along
company
management
available
discuss
year
international
world
muscle
society
wms
virtual
congress
october
et
dmd
genetic
disorder
characterized
progressive
weakness
chronic
inflammation
skeletal
heart
respiratory
muscles
patients
suffering
dmd
typically
lose
ability
walk
teenage
years
generally
die
cardiac
respiratory
complications
age
one
common
rare
diseases
currently
thousands
patients
across
country
suffering
immobilizing
effects
dmd
said
linda
marb√°n
chief
executive
officer
capricor
lead
asset
potential
exert
immunomodulatory
activity
capricor
steadfast
mission
establish
treatment
path
alleviate
symptoms
overall
better
quality
life
boys
young
adults
battling
dmd
continue
discuss
program
fda
determine
next
steps
pathway
forward
towards
potential
approval
proud
present
data
prestigious
industry
event
like
wms
raise
awareness
debilitating
disease
may
capricor
announced
positive
topline
results
clinical
trial
using
treat
patients
advanced
stages
dmd
data
showed
improvements
upper
limb
cardiac
respiratory
function
less
multiple
measures
data
showed
statistically
meaningful
improvements
pul
patients
mean
change
points
placebo
patients
exception
steroids
preservation
function
dmd
uncommon
placebo
patients
declined
consistent
natural
history
treated
group
patients
stable
showed
improvement
function
throughout
treatment
period
international
virtual
congress
world
muscle
society
take
place
september
october
capricor
made
available
attendees
wms
conference
company
website
presentation
capricor
therapeutics
capricor
therapeutics
nasdaq
capr
biotechnology
company
focused
discovery
development
commercialization
cell
therapeutics
treatment
prevention
diseases
capricor
lead
candidate
allogeneic
cell
therapy
currently
clinical
development
treatment
duchenne
muscular
dystrophy
cytokine
storm
associated
capricor
also
investigating
field
extracellular
vesicles
exploring
potential
candidates
treat
prevent
variety
disorders
developing
two
potential
vaccines
part
exosome
platform
information
visit
follow
company
facebook
instagram
twitter
consists
allogeneic
cells
cdcs
type
cardiac
cell
therapy
shown
clinical
studies
exert
potent
immunomodulatory
activity
investigated
potential
modify
immune
system
activity
encourage
cellular
regeneration
cells
function
releasing
exosomes
taken
largely
macrophages
begin
cycle
repair
cdcs
subject
scientific
publications
administered
approximately
human
subjects
across
several
clinical
trials
randomized
phase
ii
clinical
trial
company
lead
investigational
therapy
boys
young
men
advanced
stages
dmd
study
patients
treated
via
intravenous
delivery
either
million
cells
per
infusion
placebo
every
months
duchenne
muscular
dystrophy
duchenne
muscular
dystrophy
devastating
genetic
disorder
causes
muscle
degeneration
leads
death
generally
age
commonly
heart
failure
occurs
one
every
live
male
births
across
races
cultures
countries
duchenne
muscular
dystrophy
afflicts
approximately
boys
young
men
around
world
treatment
options
limited
cure
cautionary
note
regarding
statements
statements
press
release
regarding
efficacy
safety
intended
utilization
capricor
product
candidates
initiation
conduct
size
timing
results
discovery
efforts
clinical
trials
pace
enrollment
clinical
trials
plans
regarding
regulatory
filings
future
research
clinical
trials
regulatory
developments
involving
products
including
ability
obtain
regulatory
approvals
otherwise
bring
products
market
plans
regarding
current
future
collaborative
activities
ownership
commercial
rights
scope
duration
validity
enforceability
intellectual
property
rights
future
royalty
streams
revenue
projections
expectations
respect
expected
use
proceeds
recently
completed
offerings
anticipated
effects
offerings
statements
capricor
management
team
future
expectations
beliefs
goals
plans
prospects
constitute
statements
within
meaning
private
securities
litigation
reform
act
statements
statements
historical
fact
including
statements
containing
words
believes
plans
could
anticipates
expects
estimates
target
would
similar
expressions
also
considered
statements
number
important
factors
could
cause
actual
results
events
differ
materially
indicated
statements
information
risks
may
impact
capricor
business
set
forth
capricor
annual
report
form
year
ended
december
filed
securities
exchange
commission
march
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
august
statements
press
release
based
information
available
capricor
date
hereof
capricor
assumes
obligation
update
statements
investigational
new
drug
approved
indications
none
capricor
candidates
approved
clinical
investigation
information
please
contact
media
contact
caitlin
kasunich
raquel
cona
kcsa
strategic
communications
ckasunich
rcona
kcsa
com
investor
contact
joyce
allaire
lifesci
advisors
llc
jallaire
